Inhibrx Biosciences, Inc.
INBX
$122.72+16.94%
End of day · as of Aug 26, 2026, 12:34 AM ET
Mkt cap
$1.28B
EV/Sales
963.8
P/E ratio
N/A
FY2025 Revenue
$1.30M
EPS (TTM)
$-8.88
Gross Margin (FY2025)
N/A
Profit Margin (FY2025)
-10773.46%
Beta
3.32
Div yield
N/A
Sector
Healthcare
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
Use this INBX research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full INBX income, balance, and cash tables.
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company in the Healthcare sector.
Latest cached Inhibrx Biosciences, Inc. (INBX) revenue for Dec 31, 2025 was $1.3M. Net income was -$140.1M. Statements: https://lician.com/financials/inbx
Inhibrx Biosciences, Inc. (INBX) market capitalization is $1.28B on the latest cached snapshot.
Inhibrx Biosciences, Inc. (INBX) cached previous close $104.94; day range $104.71 – $126.50; volume 509,419. Session quote: https://lician.com/quote/inbx
The latest cached INBX filing is 8-K · Sep 28, 2026. Filings: https://lician.com/sec/inbx